Whole blood

Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, November 14, 2023
Annual general meeting, Bone marrow, Phenotype, ASH, Patient, Cell, Research, NF, Marketing, Therapy, CMS, Diagnosis, Safety, Rituximab, Myelocyte, SITC, CD20, ATM, Kinetics, UCLA Health, Society, Health, Courage, Corporation, Pivotal, UCB, Fibroblast, Whole blood, Immune reconstitution inflammatory syndrome, Partnership, NAM, Ronald Reagan, Medicare, Policy, FDA, Immunotherapy, Survival, Toxic epidermal necrolysis, Cancer immunotherapy, Lymphoma, Mesa, Video game, Pharmaceutical industry, Dentistry, Vaccine, Mobile phone, Transplant, NK

BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today reported financial results for the quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today reported financial results for the quarter ended September 30, 2023, and provided a business update.
  • “The third quarter marked the first patients receiving Omisirge following FDA approval and the point at which Gamida Cell truly transitioned to a commercial-stage company with our first revenue reported,” said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell.
  • The company reported revenue for the delivery of two units of Omisirge in the third quarter of 2023 and projects revenue from a total of four to six units for full year 2023.
  • Annual shareholders meeting: Gamida Cell held its Annual General Meeting of Shareholders in New York City on October 19.

Cytovia Therapeutics Presents New Data on CD38-Targeted Flex-NK™ Bispecific Antibody at 2022 American Society of Hematology Annual Meeting

Retrieved on: 
Friday, December 9, 2022
Lynx, Laboratory, Therapy, Ink, Multiple myeloma, National Cancer Institute, INSERM, Society, Cancer, Macrophage, Deep learning, CAR, Lymphatic system, Cornerstone, Natural killer T cell, BCMA, Standard of care, American Society of Hematology, Poster, Partnership, TALEN, Cell, Bone marrow, Multimedia, B cell, Immunotherapy, Transplant, Cellectis, Daratumumab, NK, Glioblastoma, Whole blood, CD38, Monoclonal antibody, Microfluidics, World Cancer Research Fund UK, ASH, Hematology, Protein, Patient, Research, UCSF, Survival, Death, Safety, HCC, CDC, Neoplasm, Vaccine, Pharmaceutical industry, ADCP, NCR1

"We're delighted to see further progress on our CD38-targeted Flex-NK bispecific antibody program, with a pre-clinical package that supports clinical evaluation in 2023," commented Cytovia CEO Dr.Daniel Teper.

Key Points: 
  • "We're delighted to see further progress on our CD38-targeted Flex-NK bispecific antibody program, with a pre-clinical package that supports clinical evaluation in 2023," commented Cytovia CEO Dr.Daniel Teper.
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II
    The poster is available online on both the Cytovia Therapeutics and American Society of Hematology websites.
  • Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive iPSC-derived Natural Killer (iNK) cell and Flex-NK bispecific antibody platforms.
  • Cytovia has developed a partnership with CytoLynx Therapeutics focused on research and development, manufacturing, and commercialization activities inGreater Chinaand beyond.

TeraImmune Presented Research on TREGable™ Technology at HCA Asia 2022

Retrieved on: 
Friday, November 18, 2022
Degenerative disease, Doctor of Philosophy, Teff, DNA, Biotechnology, TFS, Patient, Atopic dermatitis, B cell, MD, ATAC, Skin, Whole blood, Manuscript, TCR, Immunology, TF, Pharmaceutical industry, Vaccine, Regulatory T cell

GERMANTOWN, Md., Nov. 18, 2022 (GLOBE NEWSWIRE) -- TeraImmune, Inc., a biotechnology company focused on the discovery and development of novel Treg-based cell therapies for autoimmune diseases, announced today that it presented data on its TREGable technology at the Human Cell Atlas Asia (HCA Asia) 2022 Meeting that took place on November 3 4 in Bangkok, Thailand.

Key Points: 
  • GERMANTOWN, Md., Nov. 18, 2022 (GLOBE NEWSWIRE) -- TeraImmune, Inc., a biotechnology company focused on the discovery and development of novel Treg-based cell therapies for autoimmune diseases, announced today that it presented data on its TREGable technology at the Human Cell Atlas Asia (HCA Asia) 2022 Meeting that took place on November 3 4 in Bangkok, Thailand.
  • Through this company sponsored study, the researchers characterized, co-cultured and expanded Treg with 25-mer DNA oligonucleotide (named TREGable technology).
  • We continue to be excited to share our highly anticipated Treg expansion technology with the world, said Yong Chan Kim, PhD, Chief Executive Officer of TeraImmune.
  • We are thrilled to be able to share our TREGable technology and look forward to preparing a manuscript for publication in a scientific journal.

Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Doctor of Philosophy, Chromosome, Private Securities Litigation Reform Act, Whole blood, 2021 Essex County Council election, Sale, CD16, Cancer, Antibody, Obinutuzumab, GLOBE, CAR, Intellectual property, Cell, Adult, Conference, NK, CD19, COVID-19, Immunotherapy, Natural killer cell, ADCC, Rituximab, Mab, Technology, CRISPR, Time, SEC, Society, Cryopreservation, Patient, SITC, Society for Immunotherapy of Cancer, Vaccine

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of two preclinical data abstracts focused on its natural killer cell pipeline and proprietary manufacturing technology at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting and Pre-Conference Programs.

Key Points: 
  • "Our presentations at this year's SITC meeting illustrate the inherent power and potential of donor-derived NK cells, said James Trager, PhD, Chief Scientific Officer of Nkarta.
  • Nkartas research team has shown that our manufacturing platform technology can expand NK cells by well over a billion-fold, while maintaining their integrity and potency.
  • In a second study, the team has also further built on the considerable potency of our CD19-directed CAR NK candidate, NKX019.
  • Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients.

TeraImmune Receives FDA IND Clearance to Initiate Phase 1/2a Clinical Trial of TI-168 for Treatment of Hemophilia A with Refractory Inhibitors

Retrieved on: 
Tuesday, October 11, 2022
TCR, VIII, IND, ADA, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Biotechnology, Whole blood, Investigational New Drug, Food, Company, Doctor of Philosophy, Atopic dermatitis, Safety, A, GLOBE, ITI, Teff, FDA, Haemophilia A, Haemophilia, Pharmaceutical industry, Vaccine, Regulatory T cell

TI-168 is a next-generation, autologous FVIII TCR-Treg cell therapy candidate to eliminate FVIII inhibitors in HA patients.

Key Points: 
  • TI-168 is a next-generation, autologous FVIII TCR-Treg cell therapy candidate to eliminate FVIII inhibitors in HA patients.
  • The multi-center, open-label, Phase 1/2a study is designed to assess the safety and efficacy of TI-168 in up to eighteen congenital hemophilia A (HA) patients with refractory inhibitors.
  • All subjects will continue to receive mandatory prophylactic emicizumab and standard of care treatment with their usual episodic agents to treat breakthrough bleeds, as needed.
  • The primary objectives are to evaluate the safety and feasibility of TI-168 and determine the maximum tolerated dose.

Insights on the Umbilical Cord Blood Banking Global Market to 2027 - Rising Applications of Cord Blood and Stem Cells in Genetic Disease Treatment is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 31, 2022
Stem Cells, Biotechnology, Alternative Medicine, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Genetics, Science, Use, Whole blood, R, Certification, Customer support, Compound annual growth rate, Investment, Business Growth Fund, Strategic management, USD, Decision-making, COVID-19, Cord blood, Technology, Market share analysis, CAGR, Acquisition, Growth, Value, Retail, Medical device

What are the inhibiting factors and impact of COVID-19 shaping the Global Umbilical Cord Blood Banking Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Umbilical Cord Blood Banking Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Umbilical Cord Blood Banking Market?
  • What is the market share of the leading vendors in the Global Umbilical Cord Blood Banking Market?
  • What modes and strategic moves are considered suitable for entering the Global Umbilical Cord Blood Banking Market?

Multi-Platinum Producer Turn Me Up YC Steps Into the Music Tech Space by Joining The Melody App

Retrieved on: 
Tuesday, May 10, 2022
Library, Wockesha, Music, Instagram, Metadata, GLOBE, Racks in the Middle, Time, YC, Publishing, Melody (Spanish singer), Melody, Whole blood, IOS, Android, CEO, Partner, Entrepreneurship

The Melody App is a discovery app for music makers and songwriters co-founded by multi-Grammy Award winning producer/songwriter Corbett ("Racks In The Middle").

Key Points: 
  • The Melody App is a discovery app for music makers and songwriters co-founded by multi-Grammy Award winning producer/songwriter Corbett ("Racks In The Middle").
  • Joining The Melody App team just made sense for what I want to do in the music industry," says Turn Me Up YC.
  • In celebration of this announcement, The Melody App is providing up and coming producers the opportunity to collaborate directly with YC through the Turn Me Up Melody contest.
  • The Melody App launched in March '21 with a $10K beat contest judged by the 2022 Grammy Nominated Producer of the Year, Hit-Boy.

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts on Utility of clonoSEQ® in MRD Testing in Blood Cancer Patients at the 63rd ASH Annual Meeting

Retrieved on: 
Thursday, December 2, 2021
Risk, Analysis, MYC, Biology, Diagnosis, Result, Financial condition report, IGHV, Physician, Bortezomib, Time, DNA, Chimeric antigen receptor T cell, B-cell maturation antigen, Bone marrow, Dexamethasone, Acute lymphoblastic leukemia, Follicular lymphoma, CAR, Completeness, Kinetics, BCL2, Cancer, Multiple myeloma, Blood, ALL, DNA sequencing, Treatment, Conversation, Research, Huntingdon, Chronic lymphocytic leukemia, Melphalan, Infection, CLIA, Subgroup, Fluctuating asymmetry, BCMA, MM, MRD, Progression-free survival, Safety, LDT, Terminology, FDA, Relapse, Recurrence, Drug discovery, Lymphatic system, De novo, Whole blood, Genetics, Disease, CLL, Medical imaging, Dietary supplement, Vaccine, Pharmaceutical industry

Minimal residual disease (MRD) refers to the small number of cancer cells that can stay in the body during and after treatment.

Key Points: 
  • Minimal residual disease (MRD) refers to the small number of cancer cells that can stay in the body during and after treatment.
  • In August 2020, clonoSEQ received additional clearance from the FDA to detect and monitor MRD in blood or bone marrow from patients with CLL.
  • The clonoSEQ Assay is a single-site test performed at Adaptive Biotechnologies.
  • For important information about the FDA-cleared uses of clonoSEQ, including the full intended use, limitations, and detailed performance characteristics, please visit www.clonoSEQ.com/technical-summary .

Gravity Diagnostics Sponsors Blood Drive with Hoxworth Blood Center and the University of Cincinnati

Retrieved on: 
Tuesday, July 13, 2021
Blood, Transfusion medicine, Branches of biology, Medical specialties, Blood donation, Apheresis, Erythrocytapheresis, Platelet, Blood product, Whole blood

COVINGTON, Ky., July 13, 2021 /PRNewswire/ --Gravity Diagnostics partnered with the Hoxworth Blood Center, a division of the University of Cincinnati, to host a blood drive in Covington, Kentucky.

Key Points: 
  • COVINGTON, Ky., July 13, 2021 /PRNewswire/ --Gravity Diagnostics partnered with the Hoxworth Blood Center, a division of the University of Cincinnati, to host a blood drive in Covington, Kentucky.
  • On July 8th, 56 Gravity employees took time out of their busy schedules to donate blood.
  • The blood drive resulted in 40 whole blood products and four double red blood products, all of which will improve and save lives in their communities.
  • Each day, Hoxworth Blood Center alone needs to collect at least 450 units of blood and 40 units of apheresis platelets to meet the needs of patients in the Tri-State area.

Hemanext® Inc. Receives CE Mark Certification for Innovative Red Blood Cell (RBC) Processing & Storage System

Retrieved on: 
Tuesday, April 13, 2021
Blood, Branches of biology, Transfusion medicine, Medical specialties, Hematology, Blood transfusion, Red blood cell, Transfusion therapy, Packed red blood cells, Whole blood

Blood center validations required for local adoption of the Hemanext ONE RBC Processing and Storage System were completed in Norway in 2020.

Key Points: 
  • Blood center validations required for local adoption of the Hemanext ONE RBC Processing and Storage System were completed in Norway in 2020.
  • It limits the O2 and CO2 levels in the storage environment.1 reduces the fuel for oxidative damage prior to and during hypoxic storage.
  • It encourages investigators to discuss potential studies with RBCs processed and stored by Hemanext ONE.\n"By obtaining CE Mark certification, Hemanext ONE promises to make available a red blood cell transfusion therapy to help patients who are in need of lifelong and regular blood transfusions.
  • It is CE-marked for the processing and storage of CPD/PAGGSM Red Blood Cells, Leukocytes Reduced (LRRBC) that have been prepared and processed with the HEMANEXT ONE system within 24-hours of collection.